Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

In trading on Tuesday, shares of Catalyst Pharmaceuticals Inc (Symbol: CPRX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $21.1648 per share.

Comparing Catalyst Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

The CATalyst Council, the veterinary industry’s leading authority on the feline market, released Volume II of its 2025 Feline Market Insights Report. This da ...

Police across Europe have dismantled a dark web drug marketplace known as 'Archetyp Market', the pan-European Europol police body said on Monday, which added that U.S. authorities had also ...

Novel catalyst cleaves carbon–fluorine bonds to break down 'forever chemicals' by Markus Bernards, Goethe University Frankfurt am Main edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

Research, published in Chem, provides a holistic understanding of the light-driven production of hydrogen gas using a nanocrystal- enzyme complex as the catalyst, and a computational framework ...

The company has collected $170 million in new capital as it seeks to help connect data centers and other businesses in the age of artificial intelligence.

Revenue Growth: Catalyst Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 43.56%.

Max Kettner, HSBC chief multi-asset strategist, joins 'Closing Bell' to discuss how the market has been performing over the last two weeks, its next move and much more.

OMAHA, Neb. — The Catalyst Building celebrated its grand opening on Wednesday afternoon. The building is located near 48th Street and Saddle Creek Road.

Surprise court ruling striking down most of President Trump's tariffs on imports could bolster stocks, according to Wall Street analysts.